Sarcoid intermediate uveitis following etanercept treatment: A case report and review of the literature

Ocular Immunology and Inflammation

Volumn 20, Issue 1, 2012, Pages 44-48

  Fonollosa, Alex ^a   Artaraz, Joseba ^a   Les, Iñigo ^a   Martinez Berriotxoa, Agustin ^a   Izquierdo, Julio Perez ^a   Lopez, Alberto Saiz ^a   Gardeazaba, Jesus ^a   Berasategui, Barbara ^a   Martinez Alday, Nerea ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Anti TNF ; Etanercept; Intermediate uveitis; Sarcoid like granulomatosis; Sarcoidosis

Indexed keywords

AZATHIOPRINE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; PREDNISONE; USTEKINUMAB;

ADULT; ARTICLE; BIOMICROSCOPY; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; GRANULOMA; GRANULOMATOSIS; HUMAN; HUMAN TISSUE; INTRAOCULAR PRESSURE; LABORATORY TEST; LYMPHADENOPATHY; OPHTHALMOSCOPY; PSORIATIC ARTHRITIS; SARCOID UVEITIS; SARCOIDOSIS; TRANSBRONCHIAL BIOPSY; ULTRASOUND; UVEITIS; VISUAL ACUITY;

ADULT; ARTHRITIS, PSORIATIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MICROSCOPY, ACOUSTIC; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOIDOSIS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, INTERMEDIATE;

EID: 84856943391     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2011.623212     Document Type: Article

References (21)

1. Ramos-Casals M, Perez-Alvarez R, Diaz Lagares C et al.; The BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmune Rev. 2010; 9: 188-193.
2. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010; 35: 751-756
3. Paiva ES, Macaluso DC, Edwards A, et al. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis. 2000;59:67-70 (Pubitemid 30303901)
4. Massara A, Cavazzini L, La Corte R. Sarcoidosis appearing during anti-tumor necrosis factor α therapy: a new "class effect" paradoxical phenomenon. Two case reports and review of the literature. Semin Arthritis Rheum. 2010; 39:313-319
5. Daïen CI, Monnier A, Claudepierre P, et al. for the Club Rheumatismes et Infammation (CRI). Sarcoid-like granulo-matosis in patients treated with tumor necrosis factor block-ers: 10 cases. Rheumatology. 2009;48:883-886
6. Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol. 2003;21:645-646 (Pubitemid 37236461)
7. Sturferlt G, Christensson B, Bynke G, et al. Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infiximab. J Rheumatol. 2007;34:2313-2314 (Pubitemid 350076897)
8. Louie GH, Chitkara P, Ward MM. Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis. 2008;67:896-898 (Pubitemid 351829400)
9. Suzuki J, Goto H. Uveitis associated with sarcoidosis exacerbated by etanercept. Jpn J Ophthalmol. 2009;53:433-444
10. Skoie IM, Wildhagen K, Omdal R. Development of sarcoi-dosis following etanercept treatment: a report of three cases. Rheumatol Int. 2010 [Epub ahead of print].
11. Wakefeld D, Zierhut M. Controversy: ocular sarcoidosis. Ocul Immunol Infamm. 2010;18:5-9
12. Imrie FR, Dick A. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18:481-486 (Pubitemid 351339402)
13. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms of cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infiximab, etanercept and adalimumab. Arthritis Rheum. 2008;58:1248-1257 (Pubitemid 351705913)
14. Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest. 1994;94:749-760.
15. Cope AP, Liblau RS, Yang XD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997;185:1573-1584 (Pubitemid 27203254)
16. Chen X, Bäumel M, Männel DN, et al. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007;179:154-161. (Pubitemid 46986529)
17. Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature. 1998;331:356-358
18. Gordon C, Ranges GE, Greenspan JS, et al. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989;52:421-434. (Pubitemid 19214178)
19. Qin HY, Chaturvedi P, Singh B. In vivo apoptosis of diabe-togenic T cells in NOD mice by IFN-gamma/TNF-alpha. Int Immunol. 2004;16:1723-1732 (Pubitemid 40003860)
20. Kim EY, Chi HH, Rajaiah R, et al. Exogenous tumour necrosis factor alpha induces suppression of autoimmune arthritis. Arthritis Res Ther. 2008;10:R38
21. Cope AP. Regulation of autoimmunity by proinfammatory cytokines. Curr Opin Immunol. 1998;10:669-676